Alternative splicing of STAT3 produces two principal isoforms, STAT3α and STAT3β, that differ in transactivation capacity and DNA-binding behavior. Whereas STAT3α is thought to be a transcriptional activator, STAT3β – due to the lack of the transactivation domain – is thought to be a transcriptional repressor.
Therefore, the relative abundance of STAT3α and STAT3β molecules within a leukocyte will be critical for immune homeostasis and for gene-therapeutic strategies targeting STAT3. This study investigates whether short-term exposure to IFN-α, IL-6/sIL-6Rα, or IL-10 alters STAT3α/STAT3β stoichiometry in purified human CD4+, CD8+, CD14+ and CD19+ cells.
We evaluated in healthy donors PBMCs the STAT3α and STAT3β mRNA and protein levels after stimulation with IFN-α, IL-6/sIL-6Rα or IL-10. For mRNA analysis, twelve candidate reference genes were assessed for stability across subsets and stimuli, with UBE2D2 identified as the most stable reference gene.
We demonstrate that at mRNA level, cytokine treatment induced STAT3α and STAT3β mRNA in a subset-dependent manner. STAT3β mRNA largely paralleled STAT3α, and crucially, the STAT3α/STAT3β mRNA ratio remained constrained within a narrow range.
Frontiers in Immunology published a clinical update in Infectious Disease on 01 Apr 2026.
The item focuses on STAT3 isoform dynamics reveal robust splice ratio maintenance across cytokine-activated human immune cells.
Review the original article for the full source wording and details.